ABBVIE

AbbVie’s Vyalev, a 24-hour continuous subcutaneous infusion of foscarbidopa and foslevodopa, approved by FDA for treating motor fluctuations in advanced Parkinson’s disease. Vyalev showed superior improvement in 'on' time without troublesome dyskinesia and decreased 'off' time compared to oral CD/LD in clinical trials.

AbbVie's Vyalev, a 24-hour subcutaneous levodopa infusion, is the first FDA-approved treatment for motor fluctuations in advanced Parkinson’s disease. It showed superior 'on' time without dyskinesia and reduced 'off' time in Phase 3 studies, with mild to moderate adverse reactions. Medicare coverage expected in H2 2025.

FDA approves VYALEV, first subcutaneous 24-hour levodopa infusion for advanced Parkinson's, addressing motor fluctuations. VYALEV showed superior 'on' time and reduced 'off' time in Phase 3 study, with mild to moderate adverse reactions.

FDA approves AbbVie's VYALEV for treating motor fluctuations in advanced Parkinson's disease, the first subcutaneous 24-hour levodopa-based infusion therapy. VYALEV showed significant improvements in 'on' time and reduced 'off' time in Phase III trials.

FDA approves subcutaneous 24-hour infusion of foscarbidopa and foslevodopa (Vyalev) for advanced Parkinson's, offering continuous levodopa delivery. The approval is based on a phase III trial showing increased 'on' time and decreased 'off' time compared to oral treatment, with common adverse reactions including infusion site events, hallucinations, and dyskinesia.

FDA approves AbbVie's Vyalev, a 24-hour infusion therapy using prodrug versions of carbidopa and levodopa for advanced Parkinson’s patients, offering continuous symptom control without surgery.

FDA approves VYALEV, the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for motor fluctuations in advanced Parkinson's disease.

FDA approves foscarbidopa/foslevodopa (Vyalev; AbbVie) for motor fluctuations in advanced Parkinson disease, the first subcutaneous 24-hour levodopa-based infusion therapy, supported by phase 3 trial results showing safety, efficacy, and improved motor symptoms.

Allergan Aesthetics announces FDA approval of Botox Cosmetic for temporary improvement in moderate to severe vertical bands connecting the jaw and neck (platysma bands) in adults, expanding its aesthetic indications beyond the face.

Therapeutic strategies targeting protein aggregation and immune response modulation show promise for ALS and related diseases. Research highlights the role of adaptive immune response, autoimmunity, and protein aggregates in ALS progression. Current therapies, including antibody-based treatments, aim to reduce protein aggregates. Emerging therapies in clinical trials target protein aggregation and immune response modulation, with some showing potential in slowing disease progression.